This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks.com featured highlights include First Watch Restaurant, NeoGenomics and Universal Stainless & Alloy Products
by Zacks Equity Research
First Watch Restaurant, NeoGenomics and Universal Stainless & Alloy Products are part of the Zacks Screen of the Week article.
3 Best Breakout Stocks to Invest in for Superlative Returns
by Tirthankar Chakraborty
First Watch Restaurant Group (FWRG), NeoGenomics (NEO), and Universal Stainless & Alloy Products (USAP) have been selected as the breakout stocks for today.
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 35.71% and 8.64%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights Portillo's, NeoGenomics and Wingstop
by Zacks Equity Research
Portillo's, NeoGenomics and Wingstop have been highlighted in this Screen of The Week article.
3 Top Stocks Likely to Exceed Estimates This Earnings Season
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap Portillo's Inc. (PTLO), NeoGenomics (NEO) and Wingstop (WING).
Zacks.com featured highlights include Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity
by Zacks Equity Research
Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity are part of the Zacks Screen of the Week article.
5 Top Stocks Likely to Come Up With Earnings Beat
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their next releases. Tap Lamb Weston (LW), NeoGenomics (NEO), Surrozen (SRZN), KE Hodlings (BEKE) and Insperity (NSP).
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 15.38% and 10.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 60% and 6.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 41% Upside in NeoGenomics (NEO): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for NeoGenomics (NEO) points to a 40.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NeoGenomics (NEO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 26.32% and 5.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ITeos Therapeutics, Inc. (ITOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
ITeos Therapeutics, Inc. (ITOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate NeoGenomics (NEO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Aug 10, 2022
by Zacks Equity Research
Companies in The News Are: NEO,H,ARMK,AHCO
NeoGenomics (NEO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 27.27% and 0.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Lags Q4 Earnings Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of -0.49% and 0.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Adma Biologics (ADMA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
NeoGenomics (NEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 13.04% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: NeoGenomics (NEO) Q1 Earnings Expected to Decline
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reata Pharmaceuticals, Inc. (RETA) Stock Jumps 14.5%: Will It Continue to Soar?
by Zacks Equity Research
Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Illumina (ILMN) Debuts TSO Comprehensive Test in Europe
by Zacks Equity Research
Illumina's (ILMN) novel CE-marked IVD kit for comprehensive genomic profiling will enable clinicians to match cancer patients with available therapies.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
NeoGenomics (NEO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of -7.69% and 0.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?